Childhood Vaccines serve as a fundamental pillar of preventive healthcare, safeguarding children against severe and potentially life-threatening illnesses. From infancy through adolescence, vaccines provide crucial immunity against a variety of pathogens, ensuring the health and well-being of young individuals as they grow and develop. The childhood immunization schedule recommended by health authorities such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) includes vaccines against a range of infectious diseases. These vaccines target diseases such as measles, mumps, rubella, polio, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib), pneumococcal disease, rotavirus, and varicella (chickenpox).
Each vaccine is carefully formulated to stimulate the body's immune system to produce protective antibodies against specific pathogens. Some vaccines contain weakened or inactivated versions of the disease-causing microorganisms, while others contain only specific components of the pathogens, such as proteins or sugars. Childhood vaccines are typically administered in a series of doses at specific ages to ensure optimal protection. This schedule is designed to coincide with the natural development of the immune system and to provide immunity before children are at risk of exposure to certain diseases.
In addition to protecting vaccinated individuals, childhood vaccines also contribute to community immunity, also known as herd immunity. By reducing the spread of infectious diseases within communities, vaccines help protect those who are unable to be vaccinated, such as infants who are too young to receive certain vaccines or individuals with compromised immune systems. Despite the overwhelming evidence of their safety and efficacy, childhood vaccines continue to face challenges such as vaccine hesitancy, misinformation, and access barriers. Public health efforts are needed to educate parents and caregivers about the importance of childhood immunization and to ensure equitable access to vaccines for all children.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States